Results 141 to 150 of about 33,638 (296)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential [PDF]

, 2012
Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is dysregulated, leading to impaired hematopoiesis and immune function.
Ostojic, Alen, Verstovsek, Srdan, Vrhovac, Radovan   +2 more
core   +2 more sources

Detection of a Lymphoproliferative Disorder With Suspected Scattergram Analysis Using the Mindray BC‐6800 Plus Automated Hematology Analyzer: A Case Report

International Journal of Laboratory Hematology, EarlyView.
Sara Sacchetti, Matteo Bellia, Valentina Zanotti, Luca Giacomini, Roberta Rolla   +4 more
wiley   +1 more source

The NLRP1 Emerges as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Cancer Types: A Comprehensive Pan‐Cancer Analysis

Cancer Medicine, Volume 14, Issue 8, April 2025.
NLRP1, a key component of the inflammasome complex, has emerged as a significant factor in cancer development. Through a systematic in silico study, we observed NLRP1 dysregulation in multiple tumor types, with significant correlations to survival outcomes, cancer‐associated fibroblast infiltration, and drug sensitivity, highlighting its potential as a
Leila Habibipour, Mahboubeh Sadeghi, Alireza Raghibi, Nima Sanadgol, Amirhossein Mohajeri Khorasani, Pegah Mousavi   +5 more
wiley   +1 more source

Profile of pomalidomide and its potential in the treatment of myelofibrosis

Therapeutics and Clinical Risk Management, 2015
Krisstina L Gowin, Ruben A Mesa Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA Abstract: Myelofibrosis, a Philadelphia-negative myeloproliferative neoplasm, is in a new treatment era after the discovery of ...
Gowin KL, Mesa RA
doaj  

Myelofibrosis and T3-thyreotoxicosis in a girl with McCune-Albright Syndrome [PDF]

, 1981
Birgit Peitersen, H Hertz, Bendt Brock Jacobsen, Simon Krabbe   +3 more
openalex   +1 more source

OncoLog, Volume 59, Number 10, October 2014 [PDF]

, 2014
New Drugs for Myeloproliferative Neoplasms Ease Suffering and Extend Life: A new class of drugs has redefined treatment for patients with myeloproliferative neoplasms by easing their symptom burden while extending their lives Neoadjuvant Targeted Therapy
Bronson, Sarah, Hale, Kathryn L., Molar-Candanosa, Roberto, Stuyck, K.   +3 more
core  

Systemic Lupus Erythematosus Presenting With Autoimmune Myelofibrosis in a Young Woman: A Case Report

Clinical Case Reports, Volume 13, Issue 4, April 2025.
ABSTRACT Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disease characterized by different clinical manifestations and often hinders rapid diagnosis. Myelofibrosis, a rare blood disorder characterized by fibrosis replacement in bone marrow and impaired hematopoiesis, is a rare complication of SLE.
Mohammad Moeini Nodeh, Zahra Rezaieyazdi, Motahhareh Karimoddini, Amir hossein Jafarian, Mozhdeh Ghamari   +4 more
wiley   +1 more source

A Case of Paroxysmal Nocturnal Hemoglabinuria(PNH) - Like Secondary Myelofibrosis with Gastric Cancer [PDF]

, 1982
Kyun Il Yoon
openalex   +1 more source

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)

Cancer, Volume 131, Issue 7, 1 April 2025.
Abstract Background Myelofibrosis (MF) significantly impacts patients’ overall survival (OS) and quality of life (QOL). This prospective study analyzed ruxolitinib dosing patterns and associated clinical outcomes in patients with MF over 12 months. Methods ROMEI, a multicenter, observational, ongoing study, enrolled 508 adult patients with MF treated ...
Massimo Breccia, Francesca Palandri, Maurizio Martelli, Francesco Mendicino, Alessandra Malato, Giuseppe A. Palumbo, Silvia Sibilla, Nicola Di Renzo, Elisabetta Abruzzese, Sergio Siragusa, Monica Crugnola, Carmine Selleri, Fabrizio Pane, Paolo Sportoletti, Bruno Martino, Stefana Impera, Alessandra Ricco, Maria Langella, Paolo Ditonno, Giuseppe Carli, Federico Itri, Anna Marina Liberati, Tiziana Urbano, Agostino Tafuri, Vita Polizzi, Domenico Pastore, Erika Morsia, Giulia Benevolo, Giorgia Micucci, Gabriella Farina, Massimiliano Bonifacio, Elena Maria Elli, Angelo Gardellini, Valerio De Stefano, Giovanni Caocci, Antonietta Pia Falcone, Daniele Vallisa, Marco Brociner, Mario Tiribelli, Gianni Binotto, Barbara Pocali, Francesco Cavazzini, Simona Tomassetti, Francesca Lunghi, Mauro Di Ianni, Alessandro Allegra, Barbara Anaclerio, Serena Mazzotta, Nicola Orofino, Filippo Gherlinzoni, Chiara Castiglioni, Marina Landoni, Diletta Valsecchi, Michela Magnoli, Paola Guglielmelli, Francesco Passamonti   +55 more
wiley   +1 more source

Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study

Clinical Pharmacology in Drug Development, Volume 14, Issue 4, Page 333-342, April 2025.
Abstract A randomized, partially blinded, placebo‐controlled, crossover study in 48 healthy adults assessed the effect of momelotinib on the heart rate‐corrected QT interval (QTc) using the Fridericia formula (QTcF). QTc was evaluated for momelotinib 200 mg (therapeutic dose), momelotinib 800 mg (supratherapeutic dose), moxifloxacin 400 mg (positive ...
Georgios Vlasakakis, Yolanda Alvarez, Timothy Hart, Yu Liu Ho, Catherine Ellis   +4 more
wiley   +1 more source